Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors
- 1 July 1998
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 354 (1), 105-111
- https://doi.org/10.1016/s0014-2999(98)00435-x
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- In Vitro Properties of a High Affinity Selective Antagonist of the VIP1 ReceptorPeptides, 1997
- Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP-27, but not PACAP-38) degradation by the neutral endopeptidase EC 3.4.24.11Biochemical Pharmacology, 1997
- The Long-Acting Vasoactive Intestinal Polypeptide Agonist RO 25-1553 Is Highly Selective of the VIP 2 Receptor SubclassPeptides, 1997
- Development of High Affinity Selective VIP1 Receptor AgonistsPeptides, 1997
- Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthmaBiopolymers, 1995
- Properties of the VIP-PACAP type II receptor stably expressed in CHO cellsRegulatory Peptides, 1994
- The activation of adenylate cyclase by pituitary adenylate cyclase activating polypeptide (PACAP) via helodermin-preferring VIP receptors in human SUP-T1 lymphoblastic membranesBiochimica et Biophysica Acta (BBA) - Biomembranes, 1991
- Preferential cleavage of amino- and carboxyl-terminal oligopeptides from vasoactive intestinal polypeptide by human recombinant enkephalinase (neutral endopeptidase, EC 3.4.24.11)Biochemical and Biophysical Research Communications, 1989
- Peptide Analogues of the Anaphylatoxin C3a; Syntheses and PropertiesBiological Chemistry Hoppe-Seyler, 1989
- Dysfunction of the Gastrointestinal Tract. Vasoactive Intestinal Peptide in Peristalsis and Sphincter FunctionAnnals of the New York Academy of Sciences, 1988